Holding pharmaceutical, medical device executives accountable as responsible corporate officers

JAMA Network

About The Study: The findings of this study suggests that federal prosecutors have exercised far less than their full capacity under the Park doctrine to sanction problematic corporate behavior that threatens patients and the public health. The objective of the doctrine is to protect patients from the harms of an unsafe or fraudulent medical marketplace by targeting the executives who run the drug or medical device companies that make revenues on these products while violating federal law, rather than have that risk borne by patients or impersonal corporate entities.

Authors: Aaron S. Kesselheim, M.D., J.D., M.P.H., of Brigham and Women’s Hospital in Boston, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/


/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.